Skip to main content
TipRanks
Go Ultimate75% OFF

Epigral Ltd (EPIGRAL) AI Stock Analysis

2 Followers
IN:EPIGRAL

Epigral Ltd

(NSE:EPIGRAL)

Select Model
Rating:61.6Neutral
Price Target:INR 1,006.00â–²(6.33% Upside)
Action:reiterated
Date:11/03/26

The overall score of 62 is constrained by a significant conflict between strong fundamentals and weak technicals. The company's robust balance sheet and reasonable valuation are the primary strengths, providing a solid financial foundation. However, the stock is in a clear downtrend, trading below all major moving averages with weak momentum, which heavily weighs on the score. The recent compression in profit margins and negative free cash flow add caution, resulting in a neutral-to-slightly-positive overall assessment.

Positive Factors
Low leverageThe substantial reduction in leverage has strengthened Epigral’s financial resilience and reduced pressure from interest obligations. A lower debt burden should preserve flexibility to fund operations, manage cyclical demand, and pursue growth without relying as heavily on external financing.
Negative Factors
Weak cash conversionNegative latest free cash flow indicates that reported profitability is not currently translating fully into cash available for reinvestment or distribution. If this persists, it could constrain internal funding and make working-capital or investment demands more burdensome.

Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:EPIGRAL-34.76%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 41.22B
Dividend Yield
0.53%
Average Volume (3M)
3,237
Price to Earnings (P/E)
14.4
Beta (1Y)
1.17
Revenue Growth
12.89%
EPS Growth
-29.38%
Country
India
Employees
1,135
Sector
General
Sector Strength
55
Industry
Chemicals

Epigral Ltd Business Overview & Revenue Model

Company Description

Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlo...

How the Company Makes Money

EPIGRAL makes money mainly by selling chemical products to business customers (B2B) in the textile manufacturing ecosystem. Its core revenue streams typically include: (1) sales of textile auxiliaries and processing chemicals (e.g., pretreatment, dye...

Epigral Ltd Financial Statement Overview

Summary

Epigral's financials are mixed. The balance sheet is a major strength (Score 85) with low debt-to-equity of 0.26 and growing equity. Cash flow is adequate (Score 65), though free cash flow turned negative due to high capex. The income statement (Score 55) shows strong historical growth but is tempered by recent gross margin contraction to 25.5% and slowing revenue growth to 2.4%.

Income Statement

55Neutral

Balance Sheet

85Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue27.85B24.95B25.50B18.94B21.69B15.50B
Gross Profit6.72B4.63B10.67B7.79B6.43B7.48B
EBITDA5.91B5.50B7.11B4.77B6.81B5.01B
Net Income2.85B3.32B3.58B1.96B3.53B2.53B
Balance Sheet
Total Assets35.85B35.05B31.52B27.94B24.32B21.24B
Cash, Cash Equivalents and Short-Term Investments70.50M54.60M965.00M31.83M142.40M250.85M
Total Debt5.70B5.72B5.93B9.64B8.79B9.93B
Total Liabilities12.21B12.84B12.48B15.40B13.63B13.98B
Stockholders Equity23.65B22.21B19.05B12.54B10.69B7.26B
Cash Flow
Free Cash Flow0-65.30M2.46B-7.90M2.10B-1.72B
Operating Cash Flow03.88B4.41B3.98B6.26B2.84B
Investing Cash Flow0-3.55B-2.62B-4.01B-4.37B-4.55B
Financing Cash Flow0-457.90M-1.64B-75.98M-2.00B1.95B

Epigral Ltd Technical Analysis

Technical Analysis SentimentNeutral
Last Price946.15

Price Trends

50DMA1018.54Negative
100DMA1063.87Negative
200DMA1063.63Negative

Market Momentum

MACD-19.98Negative
RSI48.93Neutral
STOCH74.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Neutral. The current price of 946.15 is above the 20-day moving average (MA) of 925.89, below the 50-day MA of 1018.54, and below the 200-day MA of 1063.63, indicating a neutral trend. The MACD of -19.98 indicates Negative momentum. The RSI at 48.93 is Neutral, neither overbought nor oversold. The STOCH value of 74.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:EPIGRAL.

Epigral Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:EPIGRAL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:INDOAMININ:INDOAMIN76OutperformINR 8.20B10.15―0.44%13.23%22.22%
IN:DEEPAKNTRIN:DEEPAKNTR65NeutralINR 217.36B20.48―0.47%25.13%99.89%
IN:VALIANTORGIN:VALIANTORG63NeutralINR 9.70B14.74――21.32%175.87%
IN:EPIGRALIN:EPIGRAL62NeutralINR 40.94B14.37―0.53%12.89%-29.38%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:GUJALKALIIN:GUJALKALI54NeutralINR 43.36B32.74―3.00%11.16%88398.04%
IN:STYRENIXIN:STYRENIX54NeutralINR 32.98B13.10―2.45%9.70%25.33%

* General Sector Average

Performance Comparison

-25%0%25%50%75%IN:EPIGRALIN:DEEPAKNTRIN:GUJALKALIIN:INDOAMININ:STYRENIXIN:VALIANTORGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:EPIGRAL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:EPIGRALEpigral Ltd946.15-514.75-35.23%
IN:DEEPAKNTRDeepak Nitrite Limited1590.00-115.21-6.76%
IN:GUJALKALIGujarat Alkalies & Chemicals Ltd.591.0051.069.46%
IN:INDOAMINIndo Amines Limited114.15-13.68-10.70%
IN:STYRENIXStyrenix Performance Materials Ltd1875.75-131.88-6.57%
IN:VALIANTORGValiant Organics Limited348.5568.5024.46%

Epigral Ltd Corporate Events

Epigral Secures CRISIL AA/Stable and A1+ Ratings on ₹1,050 Crore Bank Facilities

Oct 29, 2026

Epigral Limited has disclosed that CRISIL Ratings has revised its credit ratings on the company’s bank loan facilities totaling Rs 1,050 crore. The long-term bank facilities have been assigned a CRISIL AA/Stable rating, while the short-term facilitie...

Epigral to Hold Q2 FY27 Earnings Call on November 2

Oct 28, 2026

Epigral Limited has scheduled a conference call on Monday, November 2, 2026, at 5:00 p.m. IST to discuss its financial results for the second quarter of fiscal year 2027 with investors and analysts. The company informed the National Stock Exchange of...

Epigral to Host Investor and Analyst Plant Visit at Dahej Facility

Oct 21, 2026

Epigral Ltd has announced that Elara Securities (India) Pvt Ltd will conduct an investor and analyst visit to the company’s manufacturing plant in Dahej, Gujarat, on 22 October 2026, with the schedule subject to change based on operational or partici...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026